Cantor Fitzgerald Reiterates Overweight Rating for Capricor Therapeutics (NASDAQ:CAPR)

Capricor Therapeutics (NASDAQ:CAPR)‘s stock had its “overweight” rating restated by stock analysts at Cantor Fitzgerald in a research report issued to clients and investors on Thursday,Benzinga reports. They presently have a $30.00 target price on the biotechnology company’s stock. Cantor Fitzgerald’s target price would indicate a potential upside of 114.33% from the stock’s previous close.

Separately, HC Wainwright reissued a “buy” rating and issued a $77.00 target price on shares of Capricor Therapeutics in a report on Monday. One investment analyst has rated the stock with a sell rating and six have given a buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $34.50.

Capricor Therapeutics Stock Performance

Shares of NASDAQ CAPR traded up $1.78 during mid-day trading on Thursday, hitting $14.00. The stock had a trading volume of 590,191 shares, compared to its average volume of 1,363,635. Capricor Therapeutics has a twelve month low of $3.52 and a twelve month high of $23.40. The company has a 50 day moving average of $14.05 and a two-hundred day moving average of $14.50. The firm has a market cap of $636.44 million, a PE ratio of -13.08 and a beta of 4.10.

Capricor Therapeutics (NASDAQ:CAPR) last posted its quarterly earnings results on Wednesday, March 19th. The biotechnology company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.31) by $0.15. Capricor Therapeutics had a negative return on equity of 112.95% and a negative net margin of 146.86%. The firm had revenue of $11.13 million during the quarter, compared to analysts’ expectations of $9.87 million. Equities research analysts predict that Capricor Therapeutics will post -1.21 EPS for the current fiscal year.

Institutional Investors Weigh In On Capricor Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. Summit Investment Advisors Inc. increased its position in Capricor Therapeutics by 54.1% during the fourth quarter. Summit Investment Advisors Inc. now owns 3,832 shares of the biotechnology company’s stock worth $53,000 after buying an additional 1,345 shares during the last quarter. Russell Investments Group Ltd. increased its holdings in shares of Capricor Therapeutics by 172.8% during the 4th quarter. Russell Investments Group Ltd. now owns 4,652 shares of the biotechnology company’s stock valued at $64,000 after acquiring an additional 2,947 shares during the last quarter. Virtus ETF Advisers LLC bought a new position in shares of Capricor Therapeutics in the 4th quarter valued at approximately $68,000. AlphaQuest LLC acquired a new stake in Capricor Therapeutics in the 4th quarter worth approximately $78,000. Finally, New York State Common Retirement Fund boosted its position in Capricor Therapeutics by 625.0% during the fourth quarter. New York State Common Retirement Fund now owns 5,800 shares of the biotechnology company’s stock worth $80,000 after purchasing an additional 5,000 shares during the period. Institutional investors and hedge funds own 21.68% of the company’s stock.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.